HLA class II polymorphism in Latin American patients with multiple sclerosis

被引:35
作者
Rojas, Olga-Lucia [1 ,2 ]
Rojas-Villarraga, Adriana [1 ]
Cruz-Tapias, Paola [1 ]
Luis Sanchez, Jorge [3 ]
Suarez-Escudero, Juan-Camilo [3 ]
Patarroyo, Manuel-Alfonso [4 ]
Anaya, Juan-Manuel [1 ]
机构
[1] Univ Rosario, Sch Med & Hlth Sci, Ctr Autoimmune Dis Res CREA, Bogota, Colombia
[2] Univ Rosario, Sch Med & Hlth Sci, Unidad Inmunol, Bogota, Colombia
[3] INDEA, Inst Neurol Antioquia, Medellin, Colombia
[4] FIDIC, Bogota, Colombia
关键词
Multiple sclerosis; HLA antigens; Meta-analysis; Myelin basic protein; Latin America; BASIC-PROTEIN PEPTIDE; EPSTEIN-BARR-VIRUS; AUTOIMMUNE-DISEASES; GENETIC SUSCEPTIBILITY; DIAGNOSTIC-CRITERIA; MYELIN ANTIGENS; T-CELLS; ALLELES; ASSOCIATION; DQB1-ASTERISK-0602;
D O I
10.1016/j.autrev.2009.11.001
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To identify HLA-DRB1 alleles contributing to susceptibility to multiple sclerosis (MS) in a Colombian population and to estimate the common effect size of HLA class II on MS susceptibility in Latin American populations through a meta-analysis. Methods: A total of 65 Colombian patients with MS and 184 matched controls were included. HLA-DRB1 typing was done using the sequence-specific oligonucleotide probe method. A bivariate and a multivariate logistic regression analyses were done. Case-control studies performed in Latin America were searched up to January 2009 through a systematic review of the literature. Effect summary odds ratios (ORs) and 95% confidence intervals (CIs) were obtained by means of the random effect model. Results: A total of 464 cases and 2581 controls from 7 studies and the results of the present study in Colombians were analyzed. HLA-DRB1*15 (OR: 2.3; 95% CI: 1.68-3.07; p<0.001) and HLA-DQB1*06 (OR: 2.2; 95% CI: 1.54-3.07; p<0.001) groups as well as DRB1*1501 (OR: 2.6; 95% CI: 1.67-4.02; p<0.001), DRB1*1503 (OR: 2.2; 95% CI: 1.39-3.62; p = 0.001) and DQB1*0602 (OR: 2.5; 95% CI: 1.66-3.71; p<0.001) alleles were found to be risk factors for MS. The myelin basic protein immunodominant sequence 221VHFFKNIVT229 was predicted to strongly and simultaneously bind to HLA-DRB1*1501 and *1503. Conclusion: The current study highlights the effect size of HLA class II in MS in Lain America and confirms similar allelic risk factors across diverse populations. Receptor-ligand interactions in the HLA-antigenic peptide complex could have potential predictive and therapeutical implications. (C) 2009 Elsevier B.V. All rights reserved.
引用
收藏
页码:407 / 413
页数:7
相关论文
共 40 条
  • [31] T-CELL RECOGNITION OF AN IMMUNODOMINANT MYELIN BASIC-PROTEIN EPITOPE IN MULTIPLE-SCLEROSIS
    OTA, K
    MATSUI, M
    MILFORD, EL
    MACKIN, GA
    WEINER, HL
    HAFLER, DA
    [J]. NATURE, 1990, 346 (6280) : 183 - 187
  • [32] HLA-DRB1 and multiple sclerosis in Argentina
    Patrucco, L.
    Larriba, J.
    Redal, M. A.
    Rojas, J. I.
    Argibay, P. F.
    Cristiano, E.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2009, 16 (03) : 427 - 429
  • [33] Preventing and curing multiple sclerosis by controlling Epstein-Barr virus infection
    Pender, Michael P.
    [J]. AUTOIMMUNITY REVIEWS, 2009, 8 (07) : 563 - 568
  • [34] NEW DIAGNOSTIC-CRITERIA FOR MULTIPLE-SCLEROSIS - GUIDELINES FOR RESEARCH PROTOCOLS
    POSER, CM
    PATY, DW
    SCHEINBERG, L
    MCDONALD, WI
    DAVIS, FA
    EBERS, GC
    JOHNSON, KP
    SIBLEY, WA
    SILBERBERG, DH
    TOURTELLOTTE, WW
    [J]. ANNALS OF NEUROLOGY, 1983, 13 (03) : 227 - 231
  • [35] Genetic and functional studies in multiple sclerosis patients from Martinique attest for a specific and direct role of the HLA-DR locus in the syndrome
    Quelvennec, E
    Bera, O
    Cabre, P
    Alizadeh, M
    Smadja, D
    Jugde, F
    Edan, G
    Semana, G
    [J]. TISSUE ANTIGENS, 2003, 61 (02): : 166 - 171
  • [36] SIDNEY J, 1995, J IMMUNOL, V154, P247
  • [37] Southwood S, 1998, J IMMUNOL, V160, P3363
  • [38] Genetic analysis of multiple sclerosis
    Walsh, EC
    Guschwan-McMahon, S
    Daly, MJ
    Hafler, DA
    Rioux, JD
    [J]. JOURNAL OF AUTOIMMUNITY, 2003, 21 (02) : 111 - 116
  • [39] Kinetic profiles of cerebrospinal fluid anti-MBP in response to intravenous MBP synthetic peptide DENP85VVHFFKNIVTP96RT in multiple sclerosis patients
    Warren, KG
    Catz, I
    [J]. MULTIPLE SCLEROSIS, 2000, 6 (05): : 300 - 311
  • [40] WUCHERPFENNIG KW, 1994, J IMMUNOL, V152, P5581